Primer: Physician Biosimilar Prescribing

Q2, 2010

NOTE: This is ISR’s third installment of our "Biosimilars Primer" series tracking high-level views of US and European physicians. Please also see Biosimilar Primers from US Payers and US pharmacists. Bundling options are available, please contact us at info@isrreports.com for more information.

This primer - designed, executed and analyzed by research professionals from the drug development and commercialization industry - sheds light on prescribers' views of biosimilars. It is based on interviews with 264 physicians in the United States and Western Europe. Respondents provided their beliefs, attitudes, intentions, and expectations on a number of biosimilar related topics including:

 Report Content:

This report is divided into four major sections

1. Regulatory Awareness

2. Safety and Efficacy

3. Perceptions of Generic and Innovator Companies

4. Prescribing Behavior

As always, an appendix of Charts and Graphs is also included within this report with responses to all questions asked in this study.